Navidea confirms FDA approval of expanded use for Lymphoseek Navidea Biopharmaceuticals announced that the FDA has approved the Supplemental New Drug Application for the expanded use of Lymphoseek Injection indicated for guiding sentinel lymph node biopsy in head and neck cancer patients with squamous cell carcinoma of the oral cavity. Lymphoseek becomes the first and only FDA-approved radiopharmaceutical application for sentinel lymph node detection and was first approved in March 2013 for lymphatic mapping in breast cancer and melanoma patients.
Navidea announces dual listing on Tel Aviv Stock Exchange Navidea Biopharmaceuticals announced that the Tel Aviv Stock Exchange has approved the new listing of Navidea's common stock on the TASE beginning on Tuesday, September 8 under the ticker symbol NAVB. The company's common stock will be listed on both the NYSE MKT in the United States and the TASE in Israel. The company also announced that, based upon Navidea's current market capitalization, it expects its shares to be subject to inclusion in five TASE equity indexes.
Navidea to register shares for dual listing on TASE Navidea Biopharmaceuticals announced that it has filed an application for registration of shares of its common stock for dual listing on the Tel-Aviv Stock Exchange, or TASE. Dual listing on the TASE is allowed in the U.S. and Israel without any additional regulatory requirements for companies whose shares are listed on certain accredited stock exchanges outside of Israel, including the NYSE MKT.